Eidos Therapeutics (EIDX) and Its Peers Head-To-Head Survey
Eidos Therapeutics (NASDAQ: EIDX) is one of 559 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Eidos Therapeutics to similar companies based on the strength of its valuation, institutional ownership, dividends, profitability, risk, earnings and analyst recommendations.
Earnings and Valuation
This table compares Eidos Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Eidos Therapeutics||N/A||-$33.29 million||-15.94|
|Eidos Therapeutics Competitors||$2.14 billion||$223.61 million||-4.21|
This is a summary of recent ratings for Eidos Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eidos Therapeutics Competitors||4764||13482||28267||1027||2.54|
Eidos Therapeutics currently has a consensus target price of $30.29, indicating a potential upside of 2.18%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.07%. Given Eidos Therapeutics’ rivals higher probable upside, analysts plainly believe Eidos Therapeutics has less favorable growth aspects than its rivals.
This table compares Eidos Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eidos Therapeutics Competitors||-1,568.91%||-834.64%||-27.64%|
Institutional & Insider Ownership
31.6% of Eidos Therapeutics shares are held by institutional investors. Comparatively, 45.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Eidos Therapeutics rivals beat Eidos Therapeutics on 7 of the 12 factors compared.
About Eidos Therapeutics
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.